Idaho Urologic Institute-Meridian — Meridian, Idaho

Idaho Urologic Institute-Meridian is a clinical research site located in Meridian, Idaho, United States 83642.

Crixeo Clinical Trials Trust Score: 35/100 (FAILING). This profile has not yet been claimed by the site owner.

Idaho Urologic Institute-Meridian has participated in 200 clinical trials with 138 currently active.

Therapeutic areas: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma.

Sponsors: National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Meridian

Browse all research sites in Idaho · View every site in Meridian

Sponsor Feasibility Report

Trust Score: 35/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Idaho Urologic Institute-Meridian?

Idaho Urologic Institute-Meridian has a Crixeo Trust Score of 35/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Idaho Urologic Institute-Meridian conducted?

Idaho Urologic Institute-Meridian has 200 clinical trials on record, with 138 currently active. Their work covers Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma.

Is Idaho Urologic Institute-Meridian accredited by Crixeo Clinical Trials?

Idaho Urologic Institute-Meridian has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Idaho Urologic Institute-Meridian?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.